Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients

被引：0
|
作者：
Zhi-li Jin
Tao He
Li Peng
Xiao-yan Wu
Di Fan
Ming Chen
Yong-zhen Fan
Yuan-lin Guo
Zhi-bing Lu
Hai-rong Wang
机构：
[1] Zhongnan Hospital of Wuhan University,Department of Cardiovascular Medicine
[2] Wuhan University,Institute of Myocardial Injury and Repair
[3] Chinese Academy of Medical Sciences & Peking Union Medical College,Cardio
来源：
Current Medical Science | 2023年 / 43卷
关键词：
PCSK9 inhibitor; complex higher-risk and indicated patients; lipoprotein(a) level; low-density lipoprotein cholesterol level; 2-year cardiovascular event rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1206 / 1212
页数：6
相关论文
共 50 条
  • [41] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):
  • [42] The relationship between plasma levels of lipoprotein(a) [Lp(a)], PCSK9 and their complex in hypercholesterolemic patients depends on the apolipoprotein(a) phenotype
    Klesareva, E. A.
    Afanasieva, O. I.
    Razova, O. A.
    Utkina, E. A.
    Afanasieva, M. I.
    Ezhov, M. V.
    Pokrovsky, S. N.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1305 - 1305
  • [43] PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
    Niessner, Alexander
    Drexel, Heinz
    EUROPEAN HEART JOURNAL, 2022, 43 (16) : 1566 - 1568
  • [44] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [45] PCSK9 inhibition in PAD patients - a rising star in secondary prevention?
    Gebauer, Katrin
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2018, 47 (02) : 157 - 157
  • [46] ODYSSEY ESCAPE: is PCSK9 inhibition the Trojan Horse for the use of lipoprotein apheresis in familial hypercholesterolaemia?
    Watts, Gerald F.
    Stefanutti, Claudia
    EUROPEAN HEART JOURNAL, 2016, 37 (48) : 3596 - 3599
  • [47] PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
    Ying, Q.
    Pang, J.
    Chan, D. C.
    Barrett, P. H. R.
    Watts, G. F.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2939 - 2939
  • [48] Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
    Waldmann, Elisa
    Wu, Liya
    Busygina, Kristina G.
    Altenhofer, Julia
    Henze, Kerstin
    Folwaczny, Alexander
    Parhofer, Klaus
    PLOS ONE, 2022, 17 (03):
  • [49] Genetically proxied PCSK9 inhibition is associated with reduced psoriatic arthritis risk
    Li, Junhong
    Li, Jianfeng
    Lin, Chengkai
    Zhou, Jiaxiang
    Wang, Jianmin
    Wang, Fuan
    Li, Haizhen
    Zhou, Zhiyu
    INFLAMMATION RESEARCH, 2024, 73 (03) : 475 - 484
  • [50] Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?
    Farnier, Michel
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
12345